Evotec SE American Depositary Shares (EVO) Stock Price

EVOStock

$1.38−61.67%52W

Market Cap$490.44M

P/E—

PEG Ratio1.42

Div yield—

Beta1.98

EVO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-64.41%

Price vs S&P 500 (4W)-6.84%

PEG Ratio1.42

VGM Score48.52

P/CF (Annual)45.82x

Book Value / Share (Quarterly)$4.20

P/TBV (Annual)1.24x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)1.61%

Cash Flow / Share (Quarterly)$-1.10

Price vs S&P 500 (YTD)-63.47%

Gross Margin (TTM)10.49%

Net Profit Margin (TTM)-27.47%

EPS (TTM)$-1.25

10-Day Avg Trading Volume1.55M

EPS Excl Extra (TTM)$-1.25

Revenue Growth (5Y)9.49%

EPS (Annual)$-0.65

ROI (Annual)-8.21%

Gross Margin (Annual)14.49%

Net Profit Margin (5Y Avg)-7.40%

Cash / Share (Quarterly)$3.06

Revenue Growth QoQ (YoY)-16.21%

ROA (Last FY)-6.04%

Revenue Growth TTM (YoY)-7.72%

EBITD / Share (TTM)$-1.54

ROE (5Y Avg)-7.99%

Operating Margin (TTM)-33.89%

Cash Flow / Share (Annual)$-0.58

P/B Ratio0.67x

P/B Ratio (Quarterly)1.34x

Net Income / Employee (Annual)$-25,481

EV / Revenue (TTM)0.80x

Net Interest Coverage (TTM)-6.37x

ROA (TTM)-11.76%

EV / EBITDA (TTM)21.66x

EPS Incl Extra (Annual)$-0.65

Current Ratio (Annual)2.07x

Quick Ratio (Quarterly)2.08x

3-Month Avg Trading Volume0.97M

52-Week Price Return-61.67%

Revenue / Employee (TTM)$176,795

Tangible BV / Share (Quarterly)$2.27

P/S Ratio (Annual)0.57x

Asset Turnover (Annual)0.46x

52-Week High$8.19

Operating Margin (5Y Avg)-4.57%

EPS Excl Extra (Annual)$-0.65

CapEx CAGR (5Y)-3.57%

Tangible BV CAGR (5Y)4.54%

26-Week Price Return-54.50%

Quick Ratio (Annual)1.96x

13-Week Price Return-27.84%

Total Debt / Equity (Annual)0.55x

Current Ratio (Quarterly)2.33x

Enterprise Value$647.28M

Revenue / Share Growth (5Y)6.38%

Asset Turnover (TTM)0.43x

Book Value / Share Growth (5Y)0.71%

Revenue / Employee (Annual)$194,419

Inventory Turnover (Annual)22.31x

Pretax Margin (Annual)-11.01%

Cash / Share (Annual)$3.14

3-Month Return Std Dev46.64%

Gross Margin (5Y Avg)19.80%

Net Income / Employee (TTM)$-48,605

EBITDA Interim CAGR (5Y)20.02%

ROE (Last FY)-12.72%

Net Interest Coverage (Annual)-11.10x

EPS Basic Excl Extra (Annual)$-0.65

P/FCF (TTM)8.84x

Receivables Turnover (TTM)5.44x

Total Debt / Equity (Quarterly)0.71x

EPS Incl Extra (TTM)$-1.25

Receivables Turnover (Annual)4.83x

ROI (TTM)-16.51%

P/S Ratio (TTM)0.63x

Pretax Margin (5Y Avg)-5.56%

Revenue / Share (Annual)$4.98

Tangible BV / Share (Annual)$4.95

Price vs S&P 500 (52W)-77.20%

Year-to-Date Return-52.92%

5-Day Price Return4.31%

EPS Normalized (Annual)$-0.65

ROA (5Y Avg)-3.63%

Net Profit Margin (Annual)-13.13%

Month-to-Date Return-17.23%

EBITD / Share (Annual)$-0.05

Operating Margin (Annual)-7.13%

LT Debt / Equity (Annual)0.24x

P/CF (TTM)26.53x

ROI (5Y Avg)-5.22%

LT Debt / Equity (Quarterly)0.62x

EPS Basic Excl Extra (TTM)$-1.25

P/TBV (Quarterly)2.48x

P/B Ratio (Annual)1.19x

Inventory Turnover (TTM)17.56x

Pretax Margin (TTM)-25.62%

Book Value / Share (Annual)$5.15

Price vs S&P 500 (13W)-30.53%

Beta1.98x

P/FCF (Annual)18.36x

Revenue / Share (TTM)$4.53

ROE (TTM)-26.46%

52-Week Low$2.70

vGradeB

gGradeD

mGradeC

vgmGradeC

EVO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.04	-$0.15	-225.00%(-$0.10)
Q1 2026	May 6, 2026	-$0.20	-$0.39	-97.14%(-$0.19)
Q4 2025	Apr 8, 2026	$0.08	$0.05	-35.71%(-$0.03)
Q3 2025	Nov 5, 2025	-$0.19	-$0.13	+28.00%(+$0.06)
Q2 2025	Aug 13, 2025	-$0.15	-$0.13	+7.69%(+$0.01)

EVO Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.75

3.58

3.42

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
EVOEvotec SE American Depositary Shares	B	D	C	0.6x	-7.7%	10.5%	—	$1.38
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Evotec SE American Depositary Shares

Evotec is a drug discovery and contract development and manufacturing organization (CDMO) that partners with pharmaceutical, biotechnology, and academic organizations across multiple therapeutic areas including oncology, central nervous system disorders, and infectious diseases. The company operates through two main segments: Shared R&D services (approximately 80% of revenue), which provides drug discovery, development, and manufacturing on both fee-for-service and collaboration-based models, and Just-Evotec Biologics (approximately 20% of revenue), which offers CDMO services for biologics. With over 5,000 employees and 18 production sites across Europe and the United States, Evotec serves as an integrated partner throughout the drug development lifecycle.